 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- D3L-002 / D3 Bio
Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1673;
In addition, the combination of D3L-002 with anti-PDL1 mAb showed more potent efficacy than Atezolizumab monotherapy (P< 0. Conclusions D3L-002 is a novel TIGIT
- D3S-001 / D3 Bio, D3L-002 / D3 Bio
Combination of D3L-002, an anti-TIGIT/PVRIG bispecific antibody, with D3S-001, a KRAS G12C inhibitor, transformed tumor microenvironment from "cold" to "hot" and achieved durable tumor remission in preclinical models. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_555;